This new data further supports the potential of NM001 against the most clinically challenging bacterial pathogens, including Pseudomonas aeruginosa, in respiratory disease. NM001 is a registration study-ready candidate intervention (acute use) for pulmonary exacerbations of CF in oral form and is anticipated to begin phase 1 development in 2022 in inhaled form for maintenance of ventilatory function in stable CF patients (chronic, continuous use). NovaBiotics continues to explore the potential of NM001 in other inflammatory-infectious respiratory disease & against non-respiratory pathogens.
The full article published in Frontiers in Cellular and Infection Microbiology as part of the Research Topic ‘Pseudomonas aeruginosa Pathogenisis: Virulence, Antibiotic Tolerance and Resistance, Stress Responses and Host-pathogen Interactions’ can be accessed here.